Birgit Weingessel1,2, Kata Mihaltz3, Pia Veronika Vécsei-Marlovits1,2. 1. Department of Ophthalmology, Hietzing Hospital, Wolkersbergenstrasse 1, 1130, Vienna, Austria. 2. Karl Landsteiner Institute of Process Optimization and QM in Cataract Surgery, Wolkersbergenstrasse 1, 1130, Vienna, Austria. 3. Department of Ophthalmology, Hietzing Hospital, Wolkersbergenstrasse 1, 1130, Vienna, Austria. kata.mihaltz@wienkav.at.
Abstract
AIM: The aim of this study was to find predictive factors of 1-year visual outcome, analyzing novel optical coherence tomography (OCT) biomarkers in exsudative age-related macular degeneration (choroidal neovascularization (CNV)) in two groups of different treatment modalities. METHODS: In all, 34 consecutive patients with new-onset CNV were randomized 1:1 to receive either ranibizumab monotherapy or ranibizumab combined with photodynamic therapy (PDT) with verteporfin. After three initial injections with ranibizumab, re-treatment was performed according to an as-needed scheme; PDT was performed once at baseline. Best-corrected visual acuity (BCVA) and OCT parameters like central macular volume (CMV), central macular thickness (or central retinal thickness (CRT)), subretinal and intraretinal fluid, fibrovascular lesion thickness, or inner segment/outer segment (IS/OS) junction were analyzed. RESULTS: After 12 months, a visual gain of 6.1 letters was found in the monotherapy group, whereas patients in the combination therapy group lost - 4.8 letters from baseline to the 12-month visit. CMV and CRT decreased considerably between baseline and month 2-3 in both groups, with a following slight increase until month 12. Additional application of PDT had negative effect to 12-month BCVA, whereas higher baseline BCVA and integrity of the IS/OS junction at month 12 had positive effect to 12-month BCVA. CONCLUSIONS: Better baseline BCVA and the integrity of IS/OS junction at 12-month visit were the most important predictive factors for final BCVA. Combination therapy caused worse final BCVA and a higher degree of IS/OS disruption.
RCT Entities:
AIM: The aim of this study was to find predictive factors of 1-year visual outcome, analyzing novel optical coherence tomography (OCT) biomarkers in exsudative age-related macular degeneration (choroidal neovascularization (CNV)) in two groups of different treatment modalities. METHODS: In all, 34 consecutive patients with new-onset CNV were randomized 1:1 to receive either ranibizumab monotherapy or ranibizumab combined with photodynamic therapy (PDT) with verteporfin. After three initial injections with ranibizumab, re-treatment was performed according to an as-needed scheme; PDT was performed once at baseline. Best-corrected visual acuity (BCVA) and OCT parameters like central macular volume (CMV), central macular thickness (or central retinal thickness (CRT)), subretinal and intraretinal fluid, fibrovascular lesion thickness, or inner segment/outer segment (IS/OS) junction were analyzed. RESULTS: After 12 months, a visual gain of 6.1 letters was found in the monotherapy group, whereas patients in the combination therapy group lost - 4.8 letters from baseline to the 12-month visit. CMV and CRT decreased considerably between baseline and month 2-3 in both groups, with a following slight increase until month 12. Additional application of PDT had negative effect to 12-month BCVA, whereas higher baseline BCVA and integrity of the IS/OS junction at month 12 had positive effect to 12-month BCVA. CONCLUSIONS: Better baseline BCVA and the integrity of IS/OS junction at 12-month visit were the most important predictive factors for final BCVA. Combination therapy caused worse final BCVA and a higher degree of IS/OS disruption.
Authors: Sara B Bloch; Morten la Cour; Birgit Sander; Louise K H Hansen; Josefine Fuchs; Henrik Lund-Andersen; Michael Larsen Journal: Acta Ophthalmol Date: 2011-10-19 Impact factor: 3.761
Authors: Peter K Kaiser; David S Boyer; Alan F Cruess; Jason S Slakter; Stefan Pilz; Annemarie Weisberger Journal: Ophthalmology Date: 2012-03-22 Impact factor: 12.079
Authors: David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Markus S Ladewig; Stefanie E Karl; Victoria Hamelmann; Hans-Martin Helb; Hendrik P N Scholl; Frank G Holz; Nicole Eter Journal: Graefes Arch Clin Exp Ophthalmol Date: 2007-08-15 Impact factor: 3.117
Authors: Miltiadis K Tsilimbaris; Maria I López-Gálvez; Roberto Gallego-Pinazo; Philippe Margaron; George N Lambrou Journal: J Ophthalmol Date: 2016-03-17 Impact factor: 1.909